Mary RileyGeneral Counsel
Expecting more out of medicine
We are a clinical-stage biopharmaceutical company combining innovative chemistry with well-validated biology to make medicines more accessible for people living with chronic autoimmune and inflammatory diseases.
We are led by an exceptional team of scientists, R&D executives and company builders with demonstrated track records of progressing programs from discovery through regulatory approval and commercialization.
Venkat Thalladi, Ph.D.Senior Vice President, Chemistry, Manufacturing & Controls
Paul FathereeSenior Vice President, Medicinal Chemistry
Richard H. Scheller, Ph.D.Chairman of the Board
Jim Scopa, J.D.Biotechnology Investor and Director
Jake Simson, Ph.D.Partner, RA Capital Management
Sharon TetlowManaging Partner, Potrero Hill Advisors
Lisa Bowers, M.H.S.A.Biotechnology Advisor and Director
Mittie Doyle, M.D., FACRChief Medical Officer, Aro Biotherapeutics
J. Kevin Judice, Ph.D.Co-Founder & Chief Executive Officer